Trial Profile
A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Bermekimab (Primary)
- Indications Carcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 13 Dec 2018 Post-hoc analysis results are presented in an XBiotech media release.
- 13 Dec 2018 According to an XBiotech media release, post-hoc analysis from this were published in the journal OncoImmunology.
- 08 May 2018 Status changed from active, no longer recruiting to completed.